KAYLYN COOLEY: Open Payments
NPI 1275268807 · DERIDDER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$339 in 20 payments from 9 companies in 2025. Trend: 2023 $459 · 2024 $80 · 2025 $339
Food & beverage: $339
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $96 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| ABBVIE INC. | 2 | $30 |
| Amgen Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Exact Sciences Corporation | 1 | $14 |
Products named: FANAPT, Wegovy, Auvelity, CAPLYTA, Ozempic, GVOKE HYPOPEN, VRAYLAR, OTEZLA.
Industry payments across LA — which companies pay providers there.
